News

Now in its second year, the ALS Society of Canada (ALS Canada), along with Kevin Daly’s friends and colleagues, welcome applications to the post-secondary ALS Canada Kevin Daly Bursary. The $2,500 bursary will be awarded to a post-secondary student whose…

This National Volunteer Week (April 14 – 20), ALS Canada wishes to recognize, celebrate, and thank our incredible volunteers who support our mission, raise funds, and help work toward a world free of ALS. This year’s theme is Every Moment…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario,…

An announcement of the top-line results from a European phase 3 clinical trial of TUDCA revealed that the primary endpoint of the study was not met as TUDCA failed to demonstrate an ability to significantly alter the progression of ALS…

Amylyx Pharmaceuticals announced that they have started a process with Health Canada to discontinue the marketing authorization for ALBRIOZA. This means that ALBRIOZA will no longer be available for new patients in Canada. People currently on the therapy in Canada…

Today, Ontario’s Minister of Finance, Peter Bethlenfalvy, presented the province’s 2024 Budget. While the initial budget announcement did not explicitly include a $6.6 million investment to implement the recommendations outlined in the Ontario Provincial ALS Program, we will continue our…

Today, Biogen Canada announced that Health Canada has accepted its New Drug Submission (NDS) for tofersen for the treatment of ALS in adults who have a pathogenic variant (also known as a mutation) in the superoxide dismutase 1 (SOD1) gene.…

Amylyx Pharmaceuticals has announced that the PHOENIX Phase 3 clinical trial of AMX0035 did not meet its primary or secondary endpoints. The results from the 48-week study, which involved participants from the United States of America and Europe, showed no…